Psychedelic drug assisted psychotherapy in patients with terminal cancer

Earlier clinical work with lysergic acid diethylamide (LSD) in the 1950s and early 1960s led Stanislav and colleagues to re-examine its use not as a chemotherapeutic agent but as an adjunct to psychotherapy. Prior studies had reported promising outcomes in alcoholism and other psychiatric disorders when LSD was embedded in psychotherapeutic frameworks, and limited reports from other investigators (notably Kast and a single case by Cohen) suggested LSD might lessen depression and apprehension in some terminal cancer patients without causing adverse medical reactions. These observations, plus the authors' own clinical experience with psychedelic-assisted psychotherapy, motivated a programme to explore the application of psychedelic drugs to the psychological care of patients with terminal malignancy. This paper sets out to describe the investigators' clinical programme treating cancer patients with LSD and with dipropyltryptamine (DPT) as an alternative, to outline the therapeutic procedures and assessment methods employed, and to present the observed psychological and analgesic effects. The study emphasises LSD and DPT administered within a preparatory-and-integration psychotherapeutic framework rather than as stand-alone pharmacological analgesia, and it highlights clinical impressions, observer-rated outcome data, and illustrative case material. The extracted text does not clearly report the total sample size in this section.

Patients were prepared for psychedelic sessions with brief but intensive psychotherapy; on average the group received 20.2 hours of therapy including preparation and the drug session. The protocol permitted repeated sessions when clinically indicated. Sessions took place in a private hospital room with the therapist and a trained psychedelic nurse present throughout. Sensory containment (eyeshades), selected classical music, and family involvement at the session termination were routine components. Family members were also seen separately to address their fears and to reduce patient isolation. Two active compounds were used. LSD was administered orally, with dosages ranging from 200 to 500 mcg (mean 301.1 mcg) and session durations typically 10–14 hours. DPT was given parenterally because it is inactive orally, with dosages between 60 and 105 mg (mean 81.4 mg) and sessions lasting about 4–6 hours. Psychotropic and analgesic medications were continued as clinically required, and no routine interruption of cytostatic, hormonal or antibiotic therapy was undertaken. Outcome assessment relied primarily on observer ratings rather than patient self‑administered psychometrics, because many patients could not complete demanding questionnaires. The investigators used a seven-domain rating instrument (developed by Pahnke and Richards) yielding scores from +6 to -6 on dimensions such as depression, psychological isolation, difficulty in management of physical complaints, acceptance of imminent death, fear of death and pain. Raters included therapists, co-therapists, attending physicians, nurses, family members and, later in the programme, an independent rater. Patients were also asked to provide subjective session accounts, and they completed a Psychedelic Drug Experience Questionnaire to assess peak experiences and other phenomenology. Attempts were made to obtain MMPI and Personal Orientation Inventory data pre- and post-treatment, but complete data were obtained only for a small fraction of patients. Analgesic use was standardised using a Narcotic Scale of Equivalent Dosages and compared for equal time periods before and after sessions. Data analysis collapsed ratings across rater categories to produce Global Indexes of distress, and pre-to-post changes in these Global Indexes were used as the primary measure of improvement. The investigators categorised change empirically (increase of 4+ points as “dramatic improvement,” 2–4 points as “moderate improvement,” and <2 points as “essentially unchanged”). The LSD subgroup was also analysed by whether a psychedelic peak experience was achieved. The extracted text does not present a clear, single statement of the total number of patients or the duration of follow-up for the whole sample.

Observer ratings showed statistically significant reductions in emotional and physical distress from pre- to post-treatment when ratings across rater groups were pooled. The comparison of pre- and post-treatment Global Indexes indicated that approximately 36% of the patients were classified as dramatically improved, 36% moderately improved, 19% essentially unchanged, and 8% showed a decrement after psychedelic therapy. Changes reported by raters were significant at the 0.001 level for many comparisons, although the text does not provide full numeric tables in the extracted material. Pain was a domain in which several rater groups (therapist, co-therapist, attending physician and nurse) reported significant post-treatment decreases, reaching the 0.001 significance level for four out of six rater categories. Despite these observer-rated reductions in pain, the comparison of narcotic consumption before and after psychedelic therapy showed only a non-significant trend toward reduction. The authors offer several possible methodological reasons for this discrepancy, including concomitant use of other psychotropics and analgesics that were not analysed, bias introduced by comparing equal calendar periods for patients whose post-treatment hospital stay varied, long-term narcotic dependence in some patients, and improved efficacy of the same narcotic doses rather than an absolute dose reduction. Phenomenologically, the psychedelic sessions resembled those previously observed in psychiatric populations, spanning aesthetic experiences, reliving of childhood memories, and profound transcendental or mystical experiences. A psychedelic peak experience—described as an intense sense of cosmic unity often preceded by agony, death and rebirth—was observed in about 25% of sessions. The investigators judged peak-experience sessions to be those most often associated with dramatic therapeutic change. Sessions with terminal patients differed from psychiatric patients mainly by a higher incidence of difficult physical problems (nausea, vomiting, incontinence, breathlessness) related to underlying disease, and by greater fatigue after long LSD sessions; this partly motivated the use of shorter-acting DPT in some cases. The extracted text includes detailed case material (for example, a multi-session case of a 58-year-old woman with metastatic breast cancer) illustrating transient and sometimes durable psychological improvements, renewed interpersonal closeness, and enhanced acceptance of illness; however, many patients later experienced disease progression and eventual death. Adverse or complicating events reported in the cases included acute diarrhoea, uncontrollable pain, incontinence, exhaustion, and in one instance termination of the session with intramuscular chlorpromazine due to exhaustion and distress. The extracted text does not provide a clear consolidated account of serious medical adverse events attributed causally to the drugs, and it does not report a formal adverse-event rate for the series.

The investigators interpret their findings as evidence that psychedelic-assisted psychotherapy, when embedded in preparatory and integrative psychotherapeutic work, can substantially reduce emotional distress in many terminal cancer patients and that it may also attenuate the subjective experience of pain. They propose several mechanisms: first, a direct modulation of the psychological component of pain (pain affect) and reduction of maladaptive anticipatory and retrospective components that amplify suffering; second, attentional and perceptual expansion that defocuses awareness from the nociceptive source; and third, transformational effects associated with psychedelic peak experiences, which can alter value hierarchies, decrease fear of death through a sense of surrender or loss of anticipatory anxiety, and open patients to transpersonal or existential frameworks that make death feel less devastating. Stanislav and colleagues emphasise that peak, transcendental experiences appeared particularly associated with profound and sometimes lasting changes in attitude and interpersonal functioning. Nevertheless, they caution that the observations are inherently impressionistic and that controlled studies are needed. The authors acknowledge several important limitations and uncertainties: heterogeneous treatment conditions (different therapists, different patient pools and differing treatment circumstances), difficulty obtaining standard psychometric data (MMPI and POI) for many patients, methodological issues in the narcotic-use comparison, potential selection and expectancy effects, limited follow-up data for many participants, and the complicating influence of advanced somatic disease which sometimes made sessions difficult or shortened follow-up. They also note practical obstacles such as negative media coverage of LSD contributing to recruitment difficulties and increased preparatory challenges. In terms of implications, the investigators suggest that earlier application of psychedelic-assisted psychotherapy in the course of malignancy, and possibly repeated sessions, might enhance therapeutic benefit. They call for controlled research designed to disentangle the contributions of the drug and the psychotherapeutic framework and to address the thorny methodological and ethical issues inherent in studying this highly sensitive population. The extracted text frames these recommendations as cautious and exploratory rather than definitive.